Overview

Clinical Endpoint Trial Investigating Once Daily and Bronchodilator Dosing

Status:
Completed
Trial end date:
2008-08-27
Target enrollment:
Participant gender:
Summary
Subjects will attend the unit for out-patient visits on Day 1, Day 7, Day 14 and Day 15 of each treatment period. The washout period between each treatment period will be a minimum of 10 days and maximum of 28 days. Subjects will participate in 3 treatment periods.
Phase:
Phase 2
Details
Lead Sponsor:
GlaxoSmithKline
Treatments:
6-((3-((dimethylamino)carbonyl)phenyl)sulfonyl)-8-methyl-4-((3-methyloxyphenyl)amino)-3-quinolinecarboxamide